Many patients with heart dysfunction have pulmonary hypertension, more so if they have enlarged hearts or irregular ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market’s revenue ...

A combination treatment may improve survival in patients with both pulmonary hypertension and pulmonary fibrosis, a study ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS-CoV-2 infection-even when standard medical tests return normal ...

Immunosuppression appears to reduce mortality among people with systemic sclerosis with pulmonary arterial hypertension but ...

Catastrophe losses contributed 13.9 points, 18.0 points, and 1.1 points to the Group, Reinsurance, and Insurance combined ratios, respectively. Attritional combined ratios of 90.2% for the Group ...